| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2-0017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L2-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2001-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84f4e307c3d530a910727cc7c7ec1daa |
| publicationDate |
2002-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2002136695-A1 |
| titleOfInvention |
Human medical treatment by aerosol inhalation of immunoglobulin A |
| abstract |
Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the aerosol administration, by metered dose inhaler or nebulizer, of by-product immunoglobulin A for the prevention or treatment of diseases including immunodeficiencies and infections. Antigen-specific monoclonal immunoglobulin A may be used. Immunoglobulin A from any of the aforementioned sources may then be coupled with recombinant J chain, and may then be additionally coupled with recombinant secretory component in order to render the immunoglobulin A more physiologically active. Immunoglobulin A, with or without J chain and secretory component, is then administered by aerosol inhalation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03097094-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11471617-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021340226-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009324723-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017021114-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016050949-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2405338-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113490509-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE48240-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015150510-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2405338-B |
| priorityDate |
2001-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |